▲ +169.50% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Magenta Therapeutics in the last 3 months. The average price target is $19.00, with a high forecast of $22.00 and a low forecast of $15.00. The average price target represents a 169.50% upside from the last price of $7.05.
The current consensus among 5 polled investment analysts is to buy stock in Magenta Therapeutics.
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.